First-in-Human Study with preclinical data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.

Nehal J Lakhani Drew W Rasco Hengbang Wang Lichuang Men Eric Liang Lei Tommy Fu Mary C Collins Ping Min Yan Yin Matthew S Davids Dajun Yang Yifan Zhai

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our data demonstrate that pelcitoclax has antitumor activity and is well tolerated, supporting its further clinical development for human solid tumors, particularly combined with agents that downregulate MCL-1.

Keyphrases

endothelial cells
squamous cell carcinoma
locally advanced
electronic health record
induced pluripotent stem cells
pluripotent stem cells
big data
small cell lung cancer
rectal cancer
neoadjuvant chemotherapy
radiation therapy
bone marrow
lymph node
data analysis
phase ii study
study protocol